Review Article

Obstetrical Antiphospholipid Syndrome: From the Pathogenesis to the Clinical and Therapeutic Implications

T. Marchetti, 1,2 M. Cohen, 1 and P. de Moerloose 2

1 Laboratory of Hormonology, Maternity, Geneva University Hospitals, 1211 Geneva 14, Switzerland
2 Haemostasis Unit, Geneva University Hospitals, 1211 Geneva 14, Switzerland

Correspondence should be addressed to T. Marchetti; tess.marchetti@hcuge.ch

Received 13 May 2013; Accepted 8 July 2013

1. Introduction

APS is an autoimmune disorder characterized by a high-risk of obstetrical complications affecting both mother and fetus [1, 2]. This condition can either be purely thrombotic, which will not be treated here, or obstetrical or it can combine both aspects of the syndrome. Clinical criteria of obstetrical APS have been revisited in Sydney in 2006 (Table 1) and include a history of three early miscarriages (<10 WG), and/or one stillbirth (>10 WG), and/or one intra-uterine growth restriction or a premature birth before 34 WG due to preeclampsia or eclampsia or placental insufficiency [3]. Furthermore, APS pregnant women have an increased risk of thrombosis [4], thrombocytopenia, and HELLP syndrome [5].

APS can be found as a single disease and is referred as “primary.” Secondary APS is associated with other autoimmune diseases, mainly systemic lupus erythematosus (SLE). Women are more commonly affected by APS than men, in primary (3.5:1 ratio) as well as in secondary APS (7:1) [6]. The prevalence of aPL is estimated to be 5% of the general population, and APS represents 0.5% [6, 7]. However, aPL is commonly found in 15% of women with recurrent pregnancy losses (RPLs), suggesting that APS is one of the most frequent acquired etiology for RPL [8].

aPL is a heterogeneous family of three autoantibodies including lupus anticoagulant (LA), anticardiolipin antibodies (aCL), and antiβ2glycoprotein-1 antibodies (antiβ2GPI Abs). As β2GPI seems the main antigen for aPL, antiβ2GPI Abs are now considered amongst the principal antibodies of the syndrome [9, 10].

During pregnancy, antiβ2GPI Abs affect trophoblastic cells directly by binding to β2GPI at the surface of trophoblastic cells [11].

aPL have been incriminated in alteration of trophoblastic cells via different mechanisms. Pathogenesis of aPL in pregnancy include thrombotic mechanisms, inflammation, apoptosis and immunomodulatory molecules impairments in trophoblast [12].

Moreover, damages of other cell types such as endometrial cells by aPL during pregnancy have also been involved [13, 14].

Nowadays, pathogenic mechanisms still remain unclear. A better understanding of cellular interactions with aPL is necessary. Because first-line treatments with LDA and
LMWH fail in about 30% of the cases, new specific therapeutics are in development [15]. The use of other medications is a matter of debate. Thus, hydroxychloroquine (HCQ), an old antimalarial drug used in SLE, has been shown to reduce antiphospholipid titers in the plasma of patients with persistent aPL [16] and to improve fetal outcomes in SLE-treated pregnant patients [17].

In this review of the literature, we discuss the clinical aspects of obstetrical APS on both mother and fetus sides, its pathogenesis, and current treatments as well as future treatment opportunities. In addition to another recent review on the same subject [18], we insist on new clinical and biological aspects of obstetrical APS. Infertility and infant development consequences are detailed as well as the potential impact of antibodies against domain I of \( \beta \)2GP1 on pregnancy. Moreover, special attention for catastrophic APS (CAPS) management is also given.

### 2. Obstetrical Manifestations of APS

In a European cohort of 1000 patients including 82% of APS women [19], Cervera et al. described the main clinical manifestations related to this syndrome during a 5-year follow-up (from 1999 to 2004). Obstetrical manifestations were very frequent; among them, prematurity and early pregnancy loss (as defined in Sydney’s criteria) were the main clinical features (28% and 18%, resp.).

Mean age of disease onset varies between studies (30–40 years), but women of childbearing age are mostly represented.

In APS, pregnancy manifestations, severity of these complications, and maternofetal outcomes vary with aPL. Ruffatti et al. have shown that high titers and triple positivity for aPL were associated with both mother and fetal complications, even when treatment was well conducted [20, 21].

Here, we detailed more specifically the clinical aspects of APS, enlightening its implications on fertility, pregnancy, and fetal development.

#### 2.1. On the Mother’s Side

Pathologies linked to APS during pregnancy include recurrent thrombotic events (RTEs) as well as specific obstetrical pathologies. The coexistence of both thrombosis and miscarriage is estimated at 2.5–5% of APS pregnancies [19].

RTEs are major problems during pregnancy because of the management they implicate and the risk of complications, such as pulmonary embolism (PE). However, thrombotic events are usually low under adequate medications in APS patients with ongoing pregnancy. Interestingly, the Nimes Obstetricians and Hematologists Antiphospholipid Syndrome (NOH-APS) observational study compared the incidence of thrombotic events in 517 women with purely obstetrical APS to 796 seronegative women with a history of pregnancy loss. The annual rate of thrombotic complications, defined by deep-venous thrombosis (DVT, 1.46%), PE (0.43%), superficial vein thrombosis (0.44%), and cerebrovascular events (transient ischemic attack and stroke, 0.32%), was found to be higher in obstetrical APS women than in control patients (resp., 0.43%, 0.12%, 0.14%, and 0.09%) [4].

Furthermore, in more than 20% of cases, APS in pregnancy may present with minor symptoms such as thrombocytopenia or livedo reticularis [19]. Low platelet counts (<100 G/L) can be difficult to deal with, especially under LMWH treatment. Therefore, special attention and close follow-up should be considered. Livedo reticularis is an affection of the skin with persistent, not reversible with rewarming, violaceous, red or blue, reticular or mottled, pattern of the skin of trunk, arms or legs [6]. This condition could be explained by a decrease in blood flow in dermic venules, partly due to microthrombosis and inflammation of vessel wall.

More specific obstetrical manifestations include severe preeclampsia, which is defined in Table 2. Preeclampsia generally affects 2–8% of pregnancy [1]. A cross-sectional study conducted in Florida on 141 286 women who delivered in 2001 showed that women with high aPL titers (n = 88) had an increased risk of preeclampsia or eclampsia (adjusted odds ratio or AOR 2.93), placenta insufficiency (AOR 4.58), and prolonged length of stay at hospital (>three days, AOR 3.93) [22].
Complications of preeclampsia include various rarer conditions such as eclampsia and hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome. Incidence of HELLP syndrome in APS patients is difficult to determine; however it seems more severe and occurs earlier in pregnancy than in patients not affected by APS [1, 5].

Finally, mothers can also be affected by catastrophic APS (CAPS). CAPS represents 1% of APS and can occur outside of pregnancy. CAPS is defined as a “thrombotic storm” secondary to microangiopathic diffuse thrombosis leading to multiorgan failure. 6% of CAPS seems to be associated with pregnancy and postpartum, but this is probably underestimated [23].

CAPS differential diagnosis can be difficult and large during pregnancy, including HELLP syndrome, thrombotic thrombocytopenic purpura (TTP), and disseminated intravascular coagulation (DIC). Since both mother and fetal outcomes are engaged, early diagnosis and management of CAPS are crucial. CAPS is indeed fatal in about 50% of cases even once aggressive therapy is started [1, 23].

2.3. Other Manifestations

2.3.1. Implantation Studies. Infertility and APS have been a controversial matter of study through the past years. The incidence of aPL in women with unexplained infertility and in vitro fertilization (IVF) failure seems significantly increased compared to control patients [24]. However, because of poorly designed studies, there is still a lack in evidence of aPL prediction on implantation or IVF outcome [25, 26]. Moreover, no study has clearly shown whether aPL could be associated with infertility so far, and precaution should be taken while interpreting positive aPL test results [24, 25].

2.3.2. On the Infant’s Side. In a prospective European multicenter registry, 134 babies born from mothers affected by APS have been followed up for 5 years (2005–2010); both clinical and biological parameters were analyzed [27].

If no child presented thrombotic episodes, 3% of them (4/134) had neuropsychological development disorders, among which one autism was diagnosed. The conclusion of the study was that these development disorders were more common in these children and that specific and close follow-up should be given.

These results should be interpreted with great caution. Because of the difficulty of diagnosis and the frequent changes in the current definition, the general population prevalence in autism is only estimated at around 1% of children [28], suggesting that the association between APS mothers and autistic children is hard to believe.

Moreover, the presence of aPL in these children is estimated at 20%, with no association with any specific clinical manifestation of APS or SLE. Long-term consequences should be evaluated prior to give further conclusion [27]. Figure 1 summarizes the different clinical manifestations of obstetrical APS described above.

### 3. Pathogenesis of aPL during Pregnancy

In APS, aPL binds to endothelial cells, platelets, and monocytes, inducing a proinflammatory and prothrombotic state responsible for thrombotic complications [29]. During pregnancy, aPL targets the placenta, especially the cytotrophoblastic cells (CT). Initially, the CT differentiates into two cell types. On one hand, the villous trophoblast will fuse to form the syncytiotrophoblast (ST), a barrier of protection between the mother and the fetus. On the other hand, the extravillous trophoblast (EVT) will progressively invade and colonize the maternal endometrium [30].

aPLs main antigen is 2GP1, a cationic protein that is normally in a “closed conformation” when free in the plasma of patients. It is composed of five homologous domains of approximately 60 amino acids each. Domains I and V are the two domains positively charged [31, 32]. During

| Table 2: Preeclampsia criteria. |
|---------------------------------|
| **Severe**                       | (i) Presence of preeclampsia as described above and at least one of the following criteria  |
| **Preeclampsia**                 | (ii) increase in SBP ≥30 mmHg or in DBP ≥15 mmHg after 20 WG, with edema and/or proteinuria |
|                                 | (iii) Proteinuria ≥5 g in a 24-hour urine sample collected at least 4 hours apart |
|                                 | (iv) Pulmonary edema or cyanosis |
|                                 | (v) Oliguria (<400 mL in 24 hours) |
|                                 | (vi) Persistent headaches |
|                                 | (vii) Epigastric pain and/or impaired liver function |
|                                 | (viii) Thrombocytopenia |
|                                 | (ix) Oligohydramnios, decreased fetal growth, or placental abruption |

2.2. On the Fetus’ Side. aPL is responsible for fetal development and growth impairments and can affect any stages of pregnancy.

In the general population, miscarriages affect about 1 to 4-5 pregnancies; however, recurrent pregnancy losses (RPLs) represent only 1% of pregnancy. Although fetal chromosomal abnormalities are the main cause of this condition, aPL is found in 15% of recurrent fetal losses, implicating that APS is one of the main acquired cause for recurrent miscarriages [8].

Stillbirth is a really rare condition in pregnancy in industrialized countries. However, in the “Euro-Phospholipid... project on 1000 patients, it affects up to 7% of APS pregnancies [19]. In the same study, IUGR due to placental insufficiency affected 11% of pregnancies and prematurity was found in 28% of pregnancies.
normal pregnancy and ST formation, anionic phospholipids are externalized at trophoblastic cell surface, leading to the binding of β2GP1 via domain V. This binding offers a potential site of actions for aPL by changing the conformation of the protein from a circular to an open form and exposing domains I to IV to the surface [9, 10, 31, 32]. In 2009, an international multicenter study tested 477 antiβ2GP1 antibody positive plasma samples for antibodies specific for domain I of β2GP1. It showed a stronger association of these specific antibodies with obstetrical morbidity compared to total antiβ2GP1 IgG antibodies (oddratio 2.4; [1.4–2.5], 95% confidence interval). However, further studies need to be performed to add this test to obstetrical APS criteria [33].

Pathogenesis of aPL on trophoblastic cells is a matter of debate and several hypotheses have been succeeding through time.

It has first been hypothesized that, as a parallel to the “thrombotic APS,” obstetrical APS was mainly linked to thrombosis. As proof, histological analysis of placenta collected from spontaneous abortions (N = 15), fetal deaths (N = 13), and live births (N = 16) from APS patients was found to have more thrombotic characteristics as compared to control placenta. However, these findings were not specific for APS, as placenta collected from women with clinical characteristics of APS but without aPL has the same histological findings [34].

Moreover, inflammation, including fibrin deposits, was more represented than thrombosis in histological analysis of placenta of APS women, suggesting another mechanism in pregnancies affected by APS [35].

Studies were then more focused on inflammation processes by aPL on trophoblastic cells and this role was confirmed by in vitro and in vivo studies [36–40]. Initiation of complement cascade by aPL and increase in C4 deposition in placenta of mice treated with aPL were strongly linked to adverse fetal outcome [36–39]. Moreover, both C4 and C5 deficient mice were protected from fetal injury when treated with aPL IgG [40].

More recently, immunomodulation has shown to play a critical role in APS. Implications of Toll-like receptors (TLRs) in autoimmune diseases offered a new perspective for the understanding of APS. TLR is a family of 10 different receptors identified in humans and is responsible for the innate immune response. They recognize specific sequences conserved in pathogens; and the main ones are considered to be TLRs 2 and 4 [41]. In thrombotic APS model, TLR 2 and TLR 4 have both been implicated in the pathological activation of endothelial cells, monocytes, and platelets [42–48]. More recently, aPL has been shown to induce both translocations of TLR 7 and TLR 8 in the endosomes of human monocytes, sensitizing both receptors to their specific ligands [49]. In obstetrical APS, TLR 4 has been implicated in the pathological activation of HTR-8 cell line, an EVT cell line, by aPL, leading to an uncontrolled inflammation and apoptosis [50].

Immunomodulation by TLR offered a new insight on how aPL triggered placental alteration. Thus, it has been shown that aPL could mediate a nonthrombotic noninflammatory trophoblast modulation, by altering directly their own properties. Trophoblastic properties implicate three different
mechanisms, defined as (a) migration, (b) invasion, and (c) differentiation [51–53].

First, Mulla et al. showed migration alteration of first trimester trophoblastic cells by monoclonal antiβ2GPI antibodies by decreasing IL-6 secretion and signal transducer activator of transcription 3 (STAT3) protein expression [54].

Invasion and proliferation impairments by aPL have also been studied in vitro. aPL has been shown to prevent HTR-8, a trophoblastic cell line, from invading on matrigel assay and to decrease integrins proteic expressions [55].

Finally, it has previously been described that antiphosphatidylserine antibodies, a type of aPL that is not part of the definition of APS, were responsible for syncytiotrophoblast fusion impairments [56]. A decrease in β-human choriongonadotropin (hCG) secretion, a hormone normally produced by ST, has also been described in term placenta [57]. In BeWo cell, a choriocarcinoma cell line, we recently showed that antiβ2GPI Abs significantly decrease cell differentiation in a dose-dependent way and that this effect was reversed by decreasing TLR 4 membranous expression (manuscript under submission).

Trophoblastic cells seem not the only cell type affected by aPL. Impaired endometrial differentiation in decidual phenotype as well as endometrial angiogenesis inhibition by aPL has also been advocated [58]. Laboratory findings on endometrial cells were different from those found on other cell types. Antiβ2GPI antibodies purified from APS patients were found to inhibit angiogenesis, VEGF secretion, and NFκB activation in a dose-dependent way in endometrial cells [13, 14]. This implicates that pathological mechanisms of aPL can differ between various cell types which could explain variations in treatment efficiency.

Pathogenesis of Antiphospholipid Antibodies in Pregnancy.

(1) Mechanisms on placental cell

(i) Thrombosis

(a) Aspecific mechanism [30]

(ii) Inflammation

(a) Complement activation [31, 33–36]

(iii) Immunomodulations

(a) TLR 4 activation by aPL [42]

(iv) Defective placentation

(a) Migration: decrease in IL-6 and STAT3 expression [50]

(b) Invasion: decrease in integrin expression [51]

(c) Differentiation: decrease in β-hCG secretion [52] and decrease in fusion [53]

(2) Mechanisms on endometrial cells [13, 14]

(i) Angiogenesis inhibition

(ii) Decrease in VEGF secretion

(iii) NFκB activation inhibition.

4. Treatments and Future Perspectives

APS pregnancies are real challenges for clinicians and therefore should be planned. Careful counseling is required and multidisciplinary management is the key to a successful pregnancy [2, 59]. APS patients already under oral anticoagulant drugs should be informed of potential teratogenic effects. Once pregnancy is confirmed, oral anticoagulation should be immediately stopped and switched to low-molecular weight heparin (LMWH) for the rest of the pregnancy. Guidelines for first-line APS treatments during pregnancy vary between countries. However, combination of low-dose aspirin (LDA) and LMWH injections is usually admitted and improves both fetal and mother outcomes [60] (Figure 2). Thus, without treatment, the chances of successful pregnancy are around 30%, 50% with LDA alone, and up to 70% with both molecules [61].

Treating infertile patients with positive aPL is a matter of debate. Studies conducted on LDA and LMWH indications in “aPL infertility” showed contradictory results. Even if heparin seems to improve implantation, there is still no evidence that these two treatments are truly effective for this indication [62, 63].

Biological roles of both aspirin and heparin are large. Nishino et al. have shown that aspirin could decrease thromboxane A2 production and prostaglandin I2 formation, two molecules implicated in pregnancy hypertension and preeclampsia [64]. More recently, aspirin has also been shown to upregulate interleukin-3 (IL-3) production. This molecule seems necessary for trophoblast invasion and placental formation [65].

Heparin actions have been summarized by Kwak-Kim et al. [66]. Heparin as LMWH are anticoagulant molecules that prevent clot formation and can be safely used during pregnancy. However, their roles are not limited to their antithrombotic properties. Among them, they have also been shown to be anti-inflammatory and anti-apoptotic molecules.

Both molecules have also their limitations. Mulla et al. showed that neither heparin nor LMWH could reverse the effects of antiβ2GPI Abs on trophoblast migration [54].

This could partly explain treatment failure in 30% of APS pregnancies. For them, the literature is poor with no evidence-based management defined. Second-line treatments include steroids, hydroxychloroquine (HCQ), intravenous immunoglobulin injections, and plasmaphereses [67, 68]. Among them all, HCQ is the safest molecule used in pregnancy [69]. This antimalarial drug is commonly used in lupus patients and has been shown to improve fetal outcome and to reduce lupus flares [16, 17]. Biologically, HCQ reduces the binding of antiβ2GPI Abs at the surface of trophoblastic cells [70]. Moreover, the expression of annexin A5, an anticoagulant molecule normally present at the trophoblastic cell surface, is reduced by antiβ2GPI Abs. HCQ has been shown to restore its expression, preventing the pathological activation of the trophoblastic cells [71]. We also have demonstrated that HCQ restored the effects of antiβ2GPI Abs on BeWo cell differentiation and decreased TLR 4 expression (manuscript under submission).
New molecules are also in development. As TLRs have been implicated in the pathological activation of different cell types in APS, specific p38 mitogen-protein kinase (p38-MAPK) and nuclear factor-κB inhibitors, two molecules implicated in intracellular signaling by aPL via TLR, have been developed [72]. However, their uses in pregnancy seem limited by the fact that the suppression of innate immunity could lead to immunosuppression and poor fetal and mother outcomes.

Finally, special attention should be given to prevention of CAPS. As this rare condition can be fatal in about 1/2 of the cases despite any treatment, prophylaxis is still the most important way to avoid IT. Asherson defined special circumstances during which APS patients required special attentions [73]:

(i) infections in APS patients should always be treated carefully;
(ii) when surgery is needed, APS patients should receive parenteral anticoagulation;
(iii) during postpartum, women should continue anticoagulation for 6 weeks.

5. Take-Home Messages

(i) Obstetrical APS is an entity with high pregnancy complications for both mother and fetus.
(ii) Counseling, multidisciplinary management, and tight follow-up are the keys to successful pregnancy.
(iii) Screening for high-risk APS patients is necessary to improve their pregnancy outcomes.
(iv) A better understanding of pathological mechanisms is necessary for therapeutic improvement.

Abbreviations

TLR 4: Toll-like receptor 4
aPL: Antiphospholipid antibodies
STAT3: Signal transducer activator of transcription 3
hCG: Hormone chorionic gonadotrophin
VEGF: Vascular endothelial growth factor
NFκB: Nuclear factor-kappa B.

References

[1] N. Costedoat-Chalumeau, G. Guettrot-Imbert, V. Leguern et al., “Pregnancy and antiphospholipid syndrome,” Revue de Medecine Interne, vol. 33, no. 4, pp. 209–216, 2012.
[2] A. Danza, G. Ruiz-Irastorza, and M. Khamashta, “Antiphospholipid syndrome in obstetrics,” Best Practice and Research: Clinical Obstetrics and Gynaecology, vol. 26, no. 1, pp. 65–76, 2012.
[3] S. Miyakis, M. D. Lockshin, T. Atsumi et al., “International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS),” Journal of Thrombosis and Haemostasis, vol. 4, no. 2, pp. 295–306, 2006.
[4] J. C. Gris, S. Bouvier, N. Molinari et al., “Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study,” Blood, vol. 119, no. 11, pp. 2624–2632, 2012.
[5] D. Le Thi Thuong, N. Tieulîé, N. Costedoat et al., "The HELLP syndrome in the antiphospholipid syndrome: retrospective study of 16 in 15 women," *Annals of the Rheumatic Diseases*, vol. 64, no. 2, pp. 273–278, 2005.

[6] R. Cervera, J. Piette, J. Font et al., "Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients," *Arthritis and Rheumatism*, vol. 46, no. 4, pp. 1009–1027, 2002.

[7] R. H. W. M. Derksen and P. G. de Groot, "The obstetric antiphospholipid syndrome," *Journal of Reproductive Immunology*, vol. 77, no. 1, pp. 41–50, 2008.

[8] R. S. Rai, L. Regan, K. Clifford et al., "Antiphospholipid antibodies and β2-glycoprotein-I in 500 women with recurrent miscarriage: results of a comprehensive screening approach," *Human Reproduction*, vol. 10, no. 8, pp. 2001–2005, 1995.

[9] P. G. de Groot and J. C. M. Meijers, "β2-Glycoprotein I: evolution, structure and function," *Journal of Thrombosis and Haemostasis*, vol. 9, no. 7, pp. 1275–1284, 2011.

[10] P. G. de Groot, J. C. M. Meijers, and R. T. Urbanus, "Recent developments in our understanding of the antiphospholipid syndrome," *International Journal of Laboratory Hematology*, vol. 34, no. 3, pp. 223–231, 2012.

[11] P. L. Meroni, N. Di Simone, C. Testoni, M. D’Asta, B. Acaia, and A. Caruso, "Antiphospholipid antibodies as cause of pregnancy loss," *Lupus*, vol. 13, no. 9, pp. 649–652, 2004.

[12] B. E. Harper, R. Willis, and S. S. Pierangelì, "Pathophysiologic mechanisms in antiphospholipid syndrome," *International Journal of Clinical Rheumatology*, vol. 6, no. 2, pp. 157–171, 2011.

[13] N. Di Simone, F. Di Nicuolo, S. D’Ippolito et al., "Antiphospholipid antibodies affect human endometrial angiogenesis," *Biology of Reproduction*, vol. 83, no. 2, pp. 212–219, 2010.

[14] S. D’Ippolito, R. Marana, F. Di Nicuolo et al., "Effect of low molecular weight heparins (LMWHs) on antiphospholipid antibodies (aPL)—mediated inhibition of endometrial angiogenesis," *PLoS ONE*, vol. 7, no. 1, Article ID e29660, 2012.

[15] D. W. Branch, R. M. Silver, J. L. Blackwell, J. C. Reading, and J. R. Scott, "Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience," *Obstetrics and Gynecology*, vol. 80, no. 4, pp. 614–620, 1992.

[16] A. Broder and C. Puttermann, "Hydroxychloroquine use is associated with lower odds of persistent positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus," *Journal of Rheumatology*, vol. 40, no. 1, pp. 30–33, 2013.

[17] P. M. Izmirdy, M. Y. Kim, C. Llanos et al., "Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine," *Annals of the Rheumatic Diseases*, vol. 69, no. 10, pp. 1827–1830, 2010.

[18] C. Galarza-Maldonado, M. R. Kourilovitch, O. M. Pérez-Fernández et al., "Obstetric antiphospholipid syndrome," *Autoimmunity Reviews*, vol. 11, no. 4, pp. 288–295, 2012.

[19] R. Cervera, M. A. Khamashta, Y. Shoenfeld et al., "Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients," *Annals of the Rheumatic Diseases*, vol. 68, no. 9, pp. 1428–1432, 2009.

[20] A. Ruffatti, A. Calligaro, A. Hoxha et al., "Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome," *Arthritis Care and Research*, vol. 62, no. 3, pp. 302–307, 2010.

[21] V. Pego, A. Banzato, E. Biron, A. Bracco, G. Denas, and A. Ruffatti, "What have we learned about antiphospholipid syndrome from patients and antiphospholipid carrier cohorts?" *Seminars in Thrombosis and Hemostasis*, vol. 38, no. 4, pp. 322–327, 2012.

[22] J. Nodler, S. R. Moolamala, E. M. Ledger, B. S. Nuwayhid, and Z. D. Mulla, "Elevated antiphospholipid antibody titers and adverse pregnancy outcomes: analysis of a population-based hospital dataset," *BMC Pregnancy and Childbirth*, vol. 9, article 11, 2009.

[23] J. A. Gómez-Puerta, J. Sanín-Blair, and C. Galarza-Maldonado, "Pregnancy and catastrophic antiphospholipid syndrome," *Clinical Reviews in Allergy and Immunology*, vol. 36, no. 2-3, pp. 85–90, 2009.

[24] K. L. Buckingham and L. W. Chamley, "A critical assessment of the role of antiphospholipid antibodies in infertility," *Journal of Reproductive Immunology*, vol. 80, no. 1-2, pp. 132–145, 2009.

[25] M. D. Hornstein, O. K. Davis, J. B. Massey, R. J. Paulson, and J. A. Collins, "Antiphospholipid antibodies and *in vitro* fertilization success: a meta-analysis," *Fertility and Sterility*, vol. 73, no. 2, pp. 330–333, 2000.

[26] M. Sanmarco, N. Bardin, L. Camoin et al., "Antigenic profile, prevalence, and clinical significance of antiphospholipid antibodies in women referred for *in vitro* fertilization," *Annals of the New York Academy of Sciences*, vol. 1108, pp. 457–465, 2007.

[27] A. Mekinian, E. Lachassine, P. Nicolaïse-Roland et al., "European registry of babies born to mothers with antiphospholipid syndrome," *Annals of the Rheumatic Diseases*, vol. 72, pp. 217–222, 2013.

[28] Autism and Developmental Disabilities Monitoring Network Surveillance Year 2008 Principal Investigators and Centers for Disease Control and Prevention, "Prevalence of Autism spectrum disorders—Autism and developmental disabilities monitoring network, 14 Sites, United States, 2008," *Morbidity and Mortality Weekly Report*, vol. 61, no. 3, pp. 1–19, 2012.

[29] B. Giannakopoulos and S. A. Krlis, "The pathogenesis of antiphospholipid syndrome," *The New England Journal of Medicine*, vol. 368, no. 11, pp. 1033–1044, 2013.

[30] D. Evain-Brion, J. Guibourdenche, V. Tsatsaris, and T. Fournier, "Human trophoblast differentiation," *Bulletin de l'Academie Nationale de Medicine*, vol. 193, no. 5, pp. 1017–1025, 2009.

[31] M. Mahler, G. L. Norman, P. L. Meroni, and M. Khamashta, "Autoantibodies to domain I of beta2 glycoprotein I: a promising candidate biomarker for risk management in antiphospholipid syndrome," *Autoimmunity Reviews*, vol. 12, no. 2, pp. 313–317, 2012.

[32] P. G. de Groot and R. T. Urbanus, "The significance of autoantibodies against β2-glycoprotein I," *Blood*, vol. 120, no. 2, pp. 266–274, 2012.

[33] B. de Laat, V. Pego, I. Pabinger et al., "The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study," *Journal of Thrombosis and Haemostasis*, vol. 7, no. 11, pp. 1767–1773, 2009.

[34] J. T. van Horn, C. Craven, K. Ward, D. W. Branch, and R. M. Silver, "Histologic features of placentas and abortion specimens from women with antiphospholipid and antiphospholipid-like syndromes," *Placenta*, vol. 25, no. 7, pp. 642–648, 2004.

[35] J. Skrzypczak, P. Jasiński, P. Wirtstein, T. Goźdźiewicz, and M. Rajewski, "Histologic changes in placenta and chorion of women with antiphospholipid syndrome and inherited thrombophilia," *Ginekologia Polska*, vol. 82, no. 9, pp. 652–663, 2011.
[36] J. M. Shamomki, J. E. Salmon, E. Hyjek, and R. N. Baergen, “Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies,” *The American Journal of Obstetrics and Gynecology*, vol. 196, no. 2, pp. 167.e1–167.e5, 2007.

[37] I. Cavazzana, N. Manuela, C. Irene et al., “Complement activation in anti-phospholipid syndrome: a clue for an inflammatory process?” *Journal of Autoimmunity*, vol. 28, no. 2-3, pp. 160–164, 2007.

[38] M. Gerosa, V. de Angelis, L. Tremoleti et al., “Complement involvement in antiphospholipid antibody-mediated placental damage: prospective study in APS pregnant women,” *Annals of the Rheumatic Diseases*, vol. 68, no. S3, article 210, 2009.

[39] D. Cohen, A. Buurma, N. N. Goemaere et al., “Classical complement activation as a footprint for murine and human antiphospholipid antibody-induced fetal loss,” *Journal of Pathology*, vol. 225, no. 4, pp. 502–511, 2011.

[40] G. Girardi, J. Berman, P. Redecha et al., “Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome,” *Journal of Clinical Investigation*, vol. 112, no. 11, pp. 1644–1654, 2003.

[41] T. Kawai and S. Akira, “Toll-like receptors and their crosstalk in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies,” *Thrombosis and Haemostasis*, vol. 88, no. 5, pp. 851–857, 2002.

[42] E. Raschi, C. Testoni, D. Bosio et al., “Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies,” *BLOOD*, vol. 101, no. 9, pp. 3495–3500, 2003.

[43] M. Vega-Ostertag, K. Casper, R. Swerlick, D. Ferrara, E. N. Harris, and S. S. Pierangeli, “Induction of TLR2 expression by inflammatory stimuli is required for endothelial cell responses to lipopeptides,” *Molecular Immunology*, vol. 46, no. 1, pp. 145–157, 2008.

[44] S. Dunoyer-Geindre, P. de Moerloose, B. Galve-de Rochemont, G. Reber, and E. K. O. Kruthof, “NFXB is an essential intermediate in the activation of endothelial cells by anti-β2-glycoprotein I antibodies,” *Thrombosis and Haemostasis*, vol. 88, no. 5, pp. 851–857, 2002.

[45] E. Raschi, C. Testoni, D. Bosio et al., “Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies,” *BLOOD*, vol. 101, no. 9, pp. 3495–3500, 2003.

[46] M. Vega-Ostertag, K. Casper, R. Swerlick, D. Ferrara, E. N. Harris, and S. S. Pierangeli, “Induction of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies,” *Arthritis and Rheumatism*, vol. 52, no. 5, pp. 1545–1554, 2005.

[47] N. Satta, S. Dunoyer-Geindre, G. Reber et al., “The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies,” *BLOOD*, vol. 109, no. 4, pp. 1507–1514, 2007.

[48] N. Satta, E. K. O. Kruthof, C. Fickentscher et al., “Toll-like receptor 2 mediates the activation of human monocytes and endothelial cells by antiphospholipid antibodies,” *BLOOD*, vol. 117, no. 20, pp. 5523–5531, 2011.

[49] K. Poulton, A. Rahman, and I. Giles, “Examining how antiphospholipid antibodies activate intracellular signaling pathways: a systematic review,” *Seminars in Arthritis and Rheumatism*, vol. 41, no. 5, pp. 720–736, 2012.

[50] N. Prinz, N. Clemens, D. Strand et al., “Antiphospholipid antibodies induce translocation of TLR7 and TLR8 to the endosome in human monocytes and plasmacytoid dendritic cells,” *BLOOD*, vol. 118, no. 8, pp. 2322–2332, 2011.

[51] M. J. Mulla, J. J. Brosens, L. W. Chamley et al., “Antiphospholipid antibodies induce a pro-inflammatory response in first trimester trophoblast via the TLR4/MyD88 pathway,” *The American Journal of Reproductive Immunology*, vol. 62, no. 2, pp. 96–111, 2009.

[52] P. L. Meroni, M. Gerosa, S. Scurati, C. Rossi, and M. O. Borghi, “Updating on the pathogenic mechanisms of the antiphospholipid antibodies-associated pregnancy loss,” *Clinical Reviews in Allergy and Immunology*, vol. 34, no. 3, pp. 332–337, 2008.

[53] P. L. Meroni, M. O. Borghi, E. Raschi, and F. Tedesco, “Pathogenesis of antiphospholipid syndrome: understanding the antibodies,” *Nature Reviews Rheumatology*, vol. 7, no. 6, pp. 330–339, 2011.

[54] P. L. Meroni, F. Tedesco, M. Locati et al., “Anti-phospholipid antibody mediated fetal loss: Still an open question from a pathogenic point of view,” *Lupus*, vol. 19, no. 4, pp. 453–456, 2010.

[55] M. J. Mulla, K. Myrtolli, J. J. Brosens et al., “Antiphospholipid antibodies limit trophoblast migration by reducing IL-6 production and STAT3 activity,” *The American Journal of Reproductive Immunology*, vol. 63, no. 5, pp. 339–348, 2010.

[56] M. Jovanović, M. Božić, T. Kovačević, L. Radijović, M. Petronijević, and L. Vićovac, “Effects of anti-phospholipid antibodies on a human trophoblast cell line (HTR-8/SVneo),” *Acta Histochemica*, vol. 112, no. 1, pp. 34–41, 2010.

[57] R. R. Adler, A. K. Ng, and N. S. Rote, “Monoclonal antiphosphatidylserine antibody inhibits intracellular fusion of the choriocarcinoma line, JAR,” *Biology of Reproduction*, vol. 53, no. 4, pp. 905–910, 1995.

[58] N. Di Simone, E. Raschi, C. Testoni et al., “Pathogenic role of anti-β2-glycoprotein I antibodies in antiphospholipid associated fetal loss: characterisation of β2-glycoprotein I binding to trophoblast cells and functional effects of anti-β2-glycoprotein I antibodies in vitro,” *Annals of the Rheumatic Diseases*, vol. 64, no. 3, pp. 462–467, 2005.

[59] J. Francis, R. Rai, N. J. Sebire et al., “Impaired expression of endometrial differentiation markers and complement regulatory proteins in patients with recurrent pregnancy loss associated with antiphospholipid syndrome,” *Molecular Human Reproduction*, vol. 12, no. 7, pp. 435–442, 2006.

[60] L. Andreoli, C. Bazzani, M. Taraborelli et al., “Pregnancy in autoimmune rheumatic diseases: the importance of counselling for old and new challenges,” *Autoimmunity Reviews*, vol. 10, no. 1, pp. 51–54, 2010.

[61] S. M. Bates, I. A. Greer, S. Middeldorp, D. L. Veenstra, A. Prabulos, and P. O. Vandvik, “VTE, thrombophilia, antithrombotic therapy, and pregnancy—antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines,” *Chest*, vol. 141, no. 2, supplement, pp. e691S–e736S, 2012.

[62] K. Bramham, B. J. Hunt, S. Germain et al., “Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome,” *Lupus*, vol. 19, no. 1, pp. 58–64, 2010.

[63] W. H. Kuteh, “Antiphospholipid antibodies and reproduction,” *Journal of Reproductive Immunology*, vol. 35, no. 2, pp. 151–171, 1997.

[64] S. M. Nelson and I. A. Greer, “The potential role of heparin in assisted conception,” *Human Reproduction Update*, vol. 14, no. 6, pp. 623–645, 2008.

[65] P. L. Meroni, M. Gerosa, S. Scurati, C. Rossi, and M. O. Borghi, “Updating on the pathogenic mechanisms of the antiphospholipid antibodies-associated pregnancy loss,” *Clinical Reviews in Allergy and Immunology*, vol. 34, no. 3, pp. 332–337, 2008.

[66] E. Nishino, T. Takagi, N. Mitsuda et al., “Effect of low-dose aspirin therapy on utero-placental blood flow and malondialdehyde (MDA) as an indicator of its therapeutic effect,” *Acta Obstetrica et Gynaecologica Japonica*, vol. 42, no. 12, pp. 1641–1647, 1990.
[65] P. Fishman, E. Falach-Vaknine, R. Zigelman et al., "Prevention of fetal loss in experimental antiphospholipid syndrome by *in vivo* administration of recombinant interleukin-3," *Journal of Clinical Investigation*, vol. 91, no. 4, pp. 1834–1837, 1993.

[66] J. Kwak-Kim, L. Socorro, M. Agcaoili et al., "Management of women with recurrent pregnancy losses and antiphospholipid antibody syndrome," *The American Journal of Reproductive Immunology*, vol. 69, no. 6, pp. 569–607, 2013.

[67] J. Alijotas-Reig, "Treatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management," *Lupus*, vol. 22, no. 1, pp. 6–17, 2013.

[68] C. Comarmond and P. Cacoub, "Antiphospholipid syndrome: from pathogenesis to novel immunomodulatory therapies," *Autoimmunity Reviews*, vol. 12, no. 7, pp. 752–757, 2012.

[69] K. Sperber, C. Hom, C. Chao, D. Shapiro, and J. Ash, "Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases," *Pediatric Rheumatology*, vol. 7, article 9, 2009.

[70] J. H. Rand, X. Wu, A. S. Quinn, P. P. Chen, J. J. Hathcock, and D. J. Taatjes, "Hydroxychloroquine directly reduces the bindin of antiphospholipid antibody-β2-glycoprotein I complexes to phospholipid bilayers," *Blood*, vol. 112, no. 5, pp. 1687–1695, 2008.

[71] J. H. Rand, X. X. Wu, A. S. Quinn et al., "Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug," *Blood*, vol. 115, no. 11, pp. 2292–2299, 2010.

[72] A. A. Mehdi, I. Uthman, and M. Khamashta, "Antiphospholipid syndrome: pathogenesis and a window of treatment opportunities in the future," *European Journal of Clinical Investigation*, vol. 40, no. 5, pp. 451–464, 2010.

[73] R. A. Asherson, "Multiorgan failure and antiphospholipid antibodies: the catastrophic antiphospholipid (Asherson's) syndrome," *Immunobiology*, vol. 210, no. 10, pp. 727–733, 2005.